Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
A patient thought to be recovering who develops renewed oliguria, breathlessness, oedema, confusion, vomiting, hypotension, severe hypertension or a rapid creatinine or potassium rise needs urgent reassessment for recurrent AKI, unresolved obstruction, congestion, sepsis or a medicine complication. Routine follow-up arrangements do not replace same-day escalation of physiological deterioration.
Synopsis
Judge kidney recovery after acute injury, communicate residual risk, restore beneficial medicines safely, and arrange proportionate biochemical, albuminuria and clinical follow-up across the hospital–primary care boundary.
Recovery is a trajectory, not a single discharge creatinine: compare with the pre-illness baseline, peak, dialysis requirement, current urine output and subsequent stability.
NICE advises monitoring creatinine after an AKI episode, with frequency based on how stable renal function is and how impaired it remains at discharge.
An apparent return to baseline does not erase risk; previous AKI predicts recurrence, later CKD and cardiovascular events, so the episode must remain visible in the record.
Key red flags
Relapsing dysfunction
A renewed rise after initial improvement may follow recurrent infection, poor intake, congestion, hypotension, urinary obstruction or a medicine change. Reapply AKI criteria and assess urgently according to the speed and physiological consequences.
Investigation priorities
01
Serial creatinine, eGFR and electrolytesFirst step
Confirm stability or continued recovery, detect recurrent injury and support medicine dosing and restart decisions.
Management branches
Before dischargeDefine recovery and hand over risk
An inpatient AKI episode is improving sufficiently for discharge or transfer to another care setting.
1. Record the credible baseline, highest stage, likely causes, peak and latest creatinine, urine-output course, complications, imaging, renal replacement therapy and residual abnormalities.
2. Reconcile every prescription and state which drugs were stopped, reduced or started, why this occurred, and the clinical and biochemical conditions for review or restart.
Kidney health reviewDetect CKD and reduce recurrent risk
The patient reaches a stable later review, often around three months, or remains abnormal sooner.
Key medicines
ACE inhibitor or angiotensin receptor blocker restartResume the previous or an appropriately reduced dose only after reviewing the continuing indication, blood pressure, volume state, creatinine and potassium; follow disease-specific and local titration guidance.
Loop diuretic reviewIndividualise the oral or intravenous dose to congestion, symptoms, blood pressure and prior response; do not use a fixed ‘renal recovery’ dose or prescribe solely to force urine output.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.